112 Notes to the financial statements 8 Other operating income 2009 2008 2007 m m m Royalty income 296 307 216 Milestone income 90 11 7 Impairment of equity investments 135 63 19 Disposal of equity investments 40 33 32 Disposal of other assets and legal settlements 539 260 181 Gain recognised on creation of ViiV Healthcare 296 Fair value adjustments on derivative financial instruments 5 10 41 Other income 14 3 17 1,135 541 475 Royalty and milestone income is principally a core of recurring income from the out-licensing of intellectual property.
Fair value adjustments on derivative financial instruments include movements on the now expired Quest collar and Theravance put and call options.
9 Operating profit 2009 2008 2007 The following items have been included in operating profit: m m m Employee costs Note 10 7,167 6,524 5,733 Advertising 923 805 744 Distribution costs 363 310 270 Depreciation of property, plant and equipment 1,130 920 796 Impairment of property, plant and equipment, net of reversals 149 256 97 Amortisation of intangible assets 432 311 226 Impairment of intangible assets, net of reversals 172 115 54 Net foreign exchange losses gains 163 145 1 Inventories: Cost of inventories included in cost of sales 6,743 5,734 4,784 Write-down of inventories 276 298 265 Reversal of prior year write-down of inventories 116 118 103 Operating lease rentals: Minimum lease payments 160 143 121 Contingent rents 13 15 13 Sub-lease payments 6 1 2 Fees payable to the companys auditor and its associates in relation to the Group see below 24.1 19.2 16.3 The reversals of prior year write-downs of inventories principally arise from the reassessment of usage or demand expectations prior to inventory expiration.
2009 2008 2007 Fees payable to the companys auditor and its associates m m m Audit of parent company and consolidated financial statements 2.0 1.6 1.8 Audit of accounts of the Groups UK and overseas subsidiaries, pursuant to legislation 10.2 9.3 7.9 Other assurance services, pursuant to legislation, including attestation under s. 404 of Sarbanes-Oxley Act 2002 3.0 2.9 2.9 Audit and assurance services 15.2 13.8 12.6 Other tax services 7.3 2.5 2.5 All other services, including regulatory, compliance and treasury related services 1.6 2.9 1.2 24.1 19.2 16.3 At 31st December 2009, the amount due to  LLP and its associates for fees yet to be invoiced was 4.9 million, comprising statutory audit 4.4 million, taxation services 0.2 million and other services 0.3 million.
In 2009, fees payable to  LLP and its associates for audit and assurance services remained flat in CER terms.
2009 2008 2007 In addition to the above, fees paid in respect of the GSK pension schemes were: m m m Audit 0.4 0.4 0.2 Other services 0.1 GSK Annual Report 2009 Financial statements P91P182
